Literature DB >> 15843450

Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s.

N Goodson1, J Marks, M Lunt, D Symmons.   

Abstract

BACKGROUND: There is increased cardiovascular disease mortality in rheumatoid arthritis. This may reflect an increased prevalence of cardiovascular disease or an increased case fatality in patients with rheumatoid arthritis.
OBJECTIVES: To examine whether rheumatoid patients with disease onset in the 1980s-1990s have increased mortality, and to compare cardiovascular admission rates in rheumatoid patients with those of the general population.
METHODS: An inception cohort of 1010 rheumatoid patients attending Stockport rheumatology clinics between 1981 and 1996 was followed up to December 2002 through the Office for National Statistics. Standardised mortality ratios (SMR) were calculated for all-cause and cause specific mortality, using the population of Stockport as reference. Cardiovascular disease admission rates were ascertained for a subgroup of patients using national hospital episode statistics; standardised cardiovascular disease admission rates (SAR) and SMRs were calculated for this subgroup.
RESULTS: 470 patients (48%) died during a median follow up of 11.4 years. All-cause mortality was increased in men (SMR = 1.45 (95% confidence interval, 1.22 to 1.71)) and women (SMR = 1.84 (1.64 to 2.05)), as was cardiovascular disease mortality in men (SMR = 1.36 (1.04 to 1.75) and women (SMR = 1.93 (1.65 to 2.26)). No difference in cardiovascular disease admission rates was observed in men (SAR 1.20 (0.89 to 1.58) or women (SAR = 1.10 (0.88 to 1.36)), despite excess cardiovascular disease mortality in this subgroup.
CONCLUSIONS: Patients with rheumatoid arthritis have reduced life expectancy and excess cardiovascular disease mortality. Nevertheless, standardised admission rates for cardiovascular disease were not raised. This suggests either that cardiovascular disease in rheumatoid arthritis has a higher case fatality than in the general population or that it often goes unrecognised before the fatal event.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843450      PMCID: PMC1755282          DOI: 10.1136/ard.2004.034777

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  33 in total

1.  Recent improvements in survival in patients with rheumatoid arthritis: better outcomes or different study designs?

Authors:  M M Ward
Journal:  Arthritis Rheum       Date:  2001-06

2.  Mortality in rheumatoid arthritis: relationship to single and composite measures of disease activity.

Authors:  J C Chehata; A B Hassell; S A Clarke; D L Mattey; M A Jones; P W Jones; P T Dawes
Journal:  Rheumatology (Oxford)       Date:  2001-04       Impact factor: 7.580

3.  Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden.

Authors:  S Wallberg-Jonsson; M L Ohman; S R Dahlqvist
Journal:  J Rheumatol       Date:  1997-03       Impact factor: 4.666

4.  Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8-14 years.

Authors:  T Sokka; T Möttönen; P Hannonen
Journal:  Scand J Rheumatol       Date:  1999       Impact factor: 3.641

5.  Mortality in a cohort of Norwegian patients with rheumatoid arthritis followed from 1977 to 1992.

Authors:  A G Kvalvik; M A Jones; D P Symmons
Journal:  Scand J Rheumatol       Date:  2000       Impact factor: 3.641

6.  No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset.

Authors:  E J Kroot; M A van Leeuwen; M H van Rijswijk; M L Prevoo; M A Van 't Hof; L B van De Putte; P L van Riel
Journal:  Ann Rheum Dis       Date:  2000-12       Impact factor: 19.103

7.  Mortality in rheumatoid arthritis: have we made an impact in 4 decades?

Authors:  S E Gabriel; C S Crowson; W M O'Fallon
Journal:  J Rheumatol       Date:  1999-12       Impact factor: 4.666

8.  Total mortality is increased in rheumatoid arthritis. A 17-year prospective study.

Authors:  T Riise; B K Jacobsen; J T Gran; H J Haga; E Arnesen
Journal:  Clin Rheumatol       Date:  2001       Impact factor: 2.980

9.  High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors.

Authors:  I D del Rincón; K Williams; M P Stern; G L Freeman; A Escalante
Journal:  Arthritis Rheum       Date:  2001-12

10.  Longterm mortality outcome in patients with rheumatoid arthritis: early presenters continue to do well.

Authors:  D P Symmons; M A Jones; D L Scott; P Prior
Journal:  J Rheumatol       Date:  1998-06       Impact factor: 4.666

View more
  75 in total

1.  Cardiovascular risk in patients with rheumatoid arthritis: assessment of several traditional risk parameters and a German risk score model.

Authors:  Janina Willers; Andreas Hahn
Journal:  Rheumatol Int       Date:  2011-11-16       Impact factor: 2.631

2.  Rheumatoid arthritis: prevalence, economics, and implications for payers and purchasers.

Authors:  Lola Butcher
Journal:  Biotechnol Healthc       Date:  2008-07

3.  Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases.

Authors:  Laura R Rekedal; Elena Massarotti; Rajesh Garg; Radhika Bhatia; Timothy Gleeson; Bing Lu; Daniel H Solomon
Journal:  Arthritis Rheum       Date:  2010-12

4.  Rheumatoid Arthritis and Mortality Among Women During 36 Years of Prospective Follow-Up: Results From the Nurses' Health Study.

Authors:  Jeffrey A Sparks; Shun-Chiao Chang; Katherine P Liao; Bing Lu; Alexander R Fine; Daniel H Solomon; Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-06       Impact factor: 4.794

5.  Rheumatologist and Primary Care Management of Cardiovascular Disease Risk in Rheumatoid Arthritis: Patient and Provider Perspectives.

Authors:  Christie M Bartels; Tonya J Roberts; Karen E Hansen; Elizabeth A Jacobs; Andrea Gilmore; Courtney Maxcy; Barbara J Bowers
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-04       Impact factor: 4.794

6.  Patterns of cardiovascular risk in rheumatoid arthritis.

Authors:  D H Solomon; N J Goodson; J N Katz; M E Weinblatt; J Avorn; S Setoguchi; C Canning; S Schneeweiss
Journal:  Ann Rheum Dis       Date:  2006-06-22       Impact factor: 19.103

Review 7.  What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology.

Authors:  W G Dixon; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2007-01-24       Impact factor: 19.103

8.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

9.  Statin therapy in rheumatoid arthritis: a cost-effectiveness and value-of-information analysis.

Authors:  Nick Bansback; Roberta Ara; Sue Ward; Aslam Anis; Hyon K Choi
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 10.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.